Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis

BACKGROUNDElevated levels of inflammatory cytokines have been associated with poor outcomes among COVID-19 patients. It is unknown, however, how these levels compare with those observed in critically ill patients with acute respiratory distress syndrome (ARDS) or sepsis due to other causes.METHODSWe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JCI insight Ročník 5; číslo 17
Hlavní autoři: Wilson, Jennifer G., Simpson, Laura J., Ferreira, Anne-Maud, Rustagi, Arjun, Roque, Jonasel, Asuni, Adijat, Ranganath, Thanmayi, Grant, Philip M., Subramanian, Aruna, Rosenberg-Hasson, Yael, Maecker, Holden T., Holmes, Susan P., Levitt, Joseph E., Blish, Catherine A., Rogers, Angela J.
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States American Society for Clinical Investigation 03.09.2020
American Society for Clinical investigation
Témata:
ISSN:2379-3708, 2379-3708
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:BACKGROUNDElevated levels of inflammatory cytokines have been associated with poor outcomes among COVID-19 patients. It is unknown, however, how these levels compare with those observed in critically ill patients with acute respiratory distress syndrome (ARDS) or sepsis due to other causes.METHODSWe used a Luminex assay to determine expression of 76 cytokines from plasma of hospitalized COVID-19 patients and banked plasma samples from ARDS and sepsis patients. Our analysis focused on detecting statistical differences in levels of 6 cytokines associated with cytokine storm (IL-1β, IL-1RA, IL-6, IL-8, IL-18, and TNF-α) between patients with moderate COVID-19, severe COVID-19, and ARDS or sepsis.RESULTSFifteen hospitalized COVID-19 patients, 9 of whom were critically ill, were compared with critically ill patients with ARDS (n = 12) or sepsis (n = 16). There were no statistically significant differences in baseline levels of IL-1β, IL-1RA, IL-6, IL-8, IL-18, and TNF-α between patients with COVID-19 and critically ill controls with ARDS or sepsis.CONCLUSIONLevels of inflammatory cytokines were not higher in severe COVID-19 patients than in moderate COVID-19 or critically ill patients with ARDS or sepsis in this small cohort. Broad use of immunosuppressive therapies in ARDS has failed in numerous Phase 3 studies; use of these therapies in unselected patients with COVID-19 may be unwarranted.FUNDINGFunding was received from NHLBI K23 HL125663 (AJR); The Bill and Melinda Gates Foundation OPP1113682 (AJR and CAB); Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Diseases #1016687 NIH/NIAID U19AI057229-16; Stanford Maternal Child Health Research Institute; and Chan Zuckerberg Biohub (CAB).
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Authorship note: JGW, LJS, and AMF are co–first authors.
ISSN:2379-3708
2379-3708
DOI:10.1172/jci.insight.140289